International Psoriasis Council

Advancing Knowledge. Improving Care.

Saakshi

Khattri

,

MBBS, MD, FAAD, FACR

Assistant Professor
Icahn School of Medicine at Mount Sinai
New York
,
New York
,
United States
Councilor Since: January 23, 2024
IPC Councilor
Dr. Saakshi Khattri is a board-certified dermatologist, rheumatologist, internist, and one of only a handful of triple-board-certified physicians across the United States. After completing her MBBS from Delhi University in India, Dr. Khattri moved to New York to complete her internal medicine residency, followed by a fellowship in rheumatology at the Albert Einstein College of Medicine in New York. During her fellowship, she realized the overlap between rheumatology and dermatology, which prompted her to think of doing additional training in dermatology. She completed a two-year research fellowship at Rockefeller University under the mentorship of Dr. Emma Guttman and Dr. James Krueger, where she conducted research in atopic dermatitis psoriasis and ran clinical trials. Dr. Khattri then completed a residency in dermatology at the Icahn School of Medicine at Mount Sinai in New York, where she served as chief resident. Throughout her training, Dr. Khattri has been involved in various research and has published several papers and textbook chapters. She has won numerous awards for her research during her residency. As the Director of Dermatology/Rheumatology, she is actively involved in research in psoriasis and psoriatic arthritis and conducts clinical trials for both conditions. Her clinical focus is on inflammatory and autoimmune skin diseases, complex medical dermatology, diseases with rheumatology/dermatology overlap, psoriasis, and psoriatic arthritis. Dr. Khattri divides her time between her clinical practice and research, which focuses on unraveling the underlying immune pathway abnormalities to develop novel biomarkers and therapeutics. In her free time, Dr. Khattri practices yoga and mindfulness.
Last Updated:
01/23/2024

Areas of Interest

Psoriatic arthritis progression and why secondary loss of efficacy happens with systemic treatment

Languages Spoken

English, Hindi

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026